Colgate-Palmolive vs Novo Nordisk

Amazon turns Thursday Night Football into full-funnel ad pitch

Amazon's Thursday Night Football (TNF) has become a key pitch for attracting both endemic and non-endemic advertisers to its broader advertising ecosystem. The platform leverages Prime Video's sports inventory, combined with Amazon's data and targeting capabilities, to offer full-funnel marketing opportunities. Advertisers like Colgate-Palmolive have seen significant success, with retargeting on Amazon's retail platform driving higher purchase rates and brand awareness. Media buyers note that TNF serves as a gateway for brands to increase spending on Amazon's DSP. Endemic brands appreciate the direct connection between ad exposure and sales data, while non-endemics use TNF to test Amazon's capabilities before expanding their media budgets. Amazon's strategy includes promoting multi-sport buys and upper/lower funnel inventory, aiming to raise ad spending ceiling among advertisers.

• Amazon's TNF has seen a 6% increase in advertisers this season and has brought over 80 brands new to TNF since 2022.
• Colgate-Palmolive re-upped its TNF partnership after a campaign with Bijan Robinson drove purchase rates up 8 times and doubled branded searches.
• TNF's week four game (Steelers-Browns) was the most-watched in history with 19% higher audience than 2025's comparable game.

10-Q Financial Filing Analysis for Colgate-Palmolive (2026-07-31)

Colgate-Palmolive reported second-quarter 2026 net sales of $5.361 billion, up 4.9% year-over-year, supported by 0.9% volume growth, 1.6% pricing gains, and a 2.4% favorable foreign exchange impact (organic sales growth reached 2.4%). GAAP operating profit declined 6.0% to $1.016 billion, weighed down by $129 million in pre-tax restructuring charges tied to the expanded Strategic Growth and Productivity Program. Excluding these charges, non-GAAP operating profit rose 5.0% to $1.145 billion with a 10 bps expansion in non-GAAP operating margin to 21.4%. Diluted earnings per share decreased to $0.86 on a GAAP basis (down from $0.91), while non-GAAP diluted EPS grew 8.0% to $0.99. Strong gross margin expansion (+140 bps to 61.5%) driven by funding-the-growth cost savings (280 bps) helped fund a 15% increase in advertising investment to $777 million. The company generated $1.742 billion in operating cash flow for the first six months of 2026 and continues to execute its $5.0 billion share repurchase program alongside regular dividend distributions.

• Q2 2026 net sales reached $5.361 billion (up 4.9% YoY; organic sales up 2.4%), with gross margin expanding 140 bps to 61.5%.
• GAAP operating profit was $1.016 billion and diluted EPS was $0.86, while non-GAAP operating profit rose 5% to $1.145 billion and non-GAAP diluted EPS reached $0.99.
• Cumulative pre-tax charges under the Strategic Growth and Productivity Program reached $318 million through June 30, 2026, targeting $200 million to $300 million in annualized savings.

Colgate-Palmolive Webcasts Fireside Chat at the Barclays 2026 Global Consumer Staples Conference

NEW YORK --(BUSINESS WIRE)--Aug. 27, 2026-- Colgate-Palmolive (NYSE:CL) Chairman, President and CEO, Noel Wallace, will participate in a fireside chat on Wednesday, September 9, 2026 at 8:15 a.m. ET at the Barclays 2026 Global Consumer Staples Conference.

6-K Financial Filing Analysis for Novo Nordisk (2026-10-19)

Novo Nordisk filed a Form 6-K on October 19, 2026, detailing weekly transaction activity under its ongoing share repurchase programme conducted in accordance with EU Market Abuse Regulation safe harbour rules. Between October 12 and October 16, 2026, the company repurchased 1,225,000 Class B shares for a total consideration of DKK 316,147,881, bringing the total accumulated under the sub-programme initiated on May 6, 2026, to 24,315,000 B shares valued at DKK 7,075,024,314. Overall, under the broader 12-month DKK 15 billion buyback programme initiated on February 4, 2026, Novo Nordisk has acquired 39,074,179 B shares for a total of DKK 10,875,024,304 at an average price of DKK 278.32 per share. Following these transactions, Novo Nordisk holds 53,114,876 treasury B shares, representing approximately 1.2% of the company's total share capital.

• Repurchased 1,225,000 Class B shares between October 12 and October 16, 2026, for a transaction value of DKK 316,147,881.
• Total capital returned via the February 4, 2026 programme reached DKK 10,875,024,304 across 39,074,179 B shares, against an authorized cap of DKK 15,000,000,000.
• Treasury share holding expanded to 53,114,876 Class B shares, accounting for 1.2% of total share capital (4,465,000,000 shares total).

Lundbeck Chair Wenzel to Step Down; Novo's Jørgensen Succeeds

H. Lundbeck A/S announced that Dorothea Wenzel will step down as Chair of the Board at the 2027 Annual General Meeting. The Board intends to appoint Lars Fruergaard Jørgensen, former CEO of Novo Nordisk, as her successor. Jørgensen will join the Board as an observer on November 10, 2026, before formal election. This leadership transition aligns with Lundbeck's Focused Innovator strategy, moving into its Scale phase. Wenzel, who has served on the Board since 2021 and as Chair since March 2025, will leave after five years of involvement. Jørgensen brings over 30 years of pharmaceutical experience, including leading Novo Nordisk's growth in diabetes and obesity care.

• Dorothea Wenzel will step down as Chair of Lundbeck's Board at the 2027 AGM.
• Lars Fruergaard Jørgensen, former CEO of Novo Nordisk, is intended to become new Chair.
• Jørgensen will join the Board as observer on November 10, 2026.

Anthropic Confirms AI Biology Wet Lab Operations

Anthropic confirmed it operates a wet biology lab where its AI models can perform physical experiments, integrating theoretical AI work with real-world lab testing. The lab, led by head of life sciences Eric Kauderer-Abrams, conducts research internally and with external partners, but explicitly avoids drug discovery to prevent competing with pharma clients like Novo Nordisk. Alongside the lab, Anthropic launched a Life Sciences Verification Program granting vetted researchers access to its advanced models. The announcement follows its April acquisition of stealth AI biotech Coefficient Bio for approximately $400 million and occurs amid industry and internal concerns about AI safety, including a researcher's resignation and CEO Dario Amodei's calls for self-regulation.

• Anthropic confirmed it operates a wet biology lab for AI-driven physical experiments.
• Anthropic's head of life sciences, Eric Kauderer-Abrams, stated the lab conducts research internally and with external partners.
• Anthropic acquired biotech startup Coefficient Bio in April 2026 for $400 million.